Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

First-line venetoclax-based regimens versus chemoimmunotherapy in chronic lymphocytic leukemia: A real-world analysis from the brazilian CLL registry

View Full Paper
Ask AI
Bookmark
Share

Authors

SNSamir NabhanMAMilton AranhaDFDanielle De Farias

Discussion

Loading...

Member takes

Overview

Retrospective analysis reveals superior time to next treatment in venetoclax-based regimens for CLL, suggesting effectiveness in real-world settings.

Key Points

  • This research aims to compare the effectiveness of venetoclax-based regimens versus chemoimmunotherapy as first-line therapies for chronic lymphocytic leukemia (CLL) using real-world data.
  • Retrospective multicenter study within the Brazilian CLL Registry.
  • Included patients with CLL receiving venetoclax-based regimens or standard chemoimmunotherapy.
  • Analyzed treatment outcomes including time to next treatment and overall survival.
  • Median follow-up was 33 months, with reported TTNT rates of 80% for venetoclax-based regimens vs 58% for CIT (P=0.006).
  • Three-year overall survival rates were similar between both treatment groups at 87% (P=0.75).
  • Patients on venetoclax-obinutuzumab showed favorable outcomes compared to those on chlorambucil.

Cite This Study

Nabhan et al. (2025) studied this question.

synapsesocial.com/papers/69362f714fa91c937236e1cbhttps://doi.org/10.1182/blood-2025-7413
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real-World Outcomes of Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia2026
  2. 2Clinical experience and safety of venetoclax in the treatment of patients with chronic lymphocytic leukemia in second and subsequent lines of therapy: Real-world data fron hemato-oncology centers  of slovakia2025
  3. 3Comparison of Venetoclax‐Based Treatments for Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia: A Single‐Center Real‐World Experience2026
  4. 4Clinical Experience with Venetoclax and Its Safety in Patients with Chronic Lymphocytic Leukemia in Later Lines of Treatment: A Multicenter Analysis from Slovakia2026
  5. 5Real‐World Safety and Efficacy of Venetoclax in Chronic Lymphocytic Leukemia: A Single‐Center Comparative Analysis With Randomized Clinical Trials2025 · 1 citations